首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1391890

整合酶抑制劑市場：按藥物、途徑、配銷通路和地區

Integrase Inhibitors Market, By Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, and Others ), By Route of Administration, By Distribution Channel, By Geography

出版日期: 2023年10月30日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年全球整合酶抑制劑市場規模為147億美元，預計2030年將達217億美元，2023年至2030年年複合成長率（CAGR）為5.7%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	147億美元
實績資料	2018-2021	預測期	2023-2030
預測期CAGR	5.70%	2030年市場規模預測	217億美元

圖 1. 2023 年整合酶抑制劑的全球市場佔有率(%)（按地區）

整合酶抑制劑是一類相對較新的抗逆轉錄病毒藥物，用於治療愛滋病毒/愛滋病。 HIV整合酶抑制劑透過特異性抑制HIV整合酶發揮作用，HIV整合酶是一種逆轉錄病毒酶，對於宿主細胞內HIV基因組的複製至關重要。整合酶抑制劑可阻止 HIV 病毒 DNA 整合到受感染細胞的染色體 DNA 中，並防止新的 HIV 病毒粒子繁殖。 Raltegravir是第一代整合酶抑制劑，於2007年核准，提供了抑制HIV複製的新作用機制。在臨床試驗中顯示出高療效和良好的耐受性。此後，新一代整合酶抑制劑，如埃替拉韋、多替拉韋等相繼被開發出來並核准。這些藥物比現有的抗愛滋病毒療法具有更好的療效和耐受性。整合酶抑制劑的引入大大擴展了愛滋病毒管理的治療選擇。整合酶抑制劑透過阻斷病毒 DNA 整合到宿主細胞 DNA 中來治療 HIV/愛滋病，主要是透過抑制稱為整合酶的病毒酶的活性。

市場動態：

全球整合酶抑制劑市場的成長主要由全球愛滋病毒/愛滋病疾病負擔的增加、愛滋病毒抗逆轉濾病毒治療（ART）的日益普及以及新的和改進的整合酶抑制劑產品平臺的推出推動。。 HIV/愛滋病盛行率的增加、藥物開發的進步、整合酶抑制劑的功效和安全性是預計在預測期內推動全球整合酶抑制劑市場成長的主要因素。已開發國家有關抗逆轉錄病毒治療應用的有利政府舉措提供了有利可圖的機會。然而，HIV抗藥性菌株的出現以及整合酶抑制劑治療的高成本可能會對市場成長產生負面影響。市場主要企業致力於長效注射/口服製劑的研究和開發，以提高治療醫囑遵從性並增加商機。

本研究的主要特點

該報告詳細分析了全球整合酶抑制劑市場，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR %）。
它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據以下參數（例如公司亮點、產品系列、主要亮點、財務實績和策略）介紹了全球整合酶抑制劑市場的主要企業。
該報告的見解使行銷人員和經營團隊負責人就未來的產品發布、類型升級、市場擴張和行銷策略做出資訊的決策。
全球整合酶抑制劑市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球整合酶抑制劑市場的各種策略矩陣，將有助於相關人員做出決策。

介紹
北美洲
美國
加拿大
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
歐洲其他地區
亞太地區
印度
中國
日本
澳洲
東南亞國協
韓國
其他亞太地區
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
北非
中部非洲
南非

第9章競爭形勢

Gilead Sciences
ViiV Healthcare group
Merck & Co., Inc
GlaxoSmithKline PLC
Bristol-Myers Squibb Company
Johnson & Johnson
AbbVie Inc
Janssen Pharmaceuticals, Inc
Theratechnologies Inc
Shionogi & Co., Ltd
Viatris Inc.

第10章章

調查方法
關於出版商

簡介目錄

Product Code: CMI6023

The global integrase inhibitors market size was valued at US$ 14.7 billion in 2023 and is expected US$ 21.7 billion by 2030 is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 14.7 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.70%	2030 Value Projection:	US$ 21.7 Bn

Figure 1. Global Integrase Inhibitors Market Share (%), By Region, 2023

Integrase inhibitors are a relatively new class of antiretroviral drugs used for the treatment of HIV/AIDS. They work by specifically inhibiting HIV integrase, a retroviral enzyme that is essential for the replication of HIV's genome in host cells. Integrase inhibitors prevent integration of HIV viral DNA into the chromosomal DNA of the infected cells, thus blocking the propagation of new HIV virions. The first generation integrase inhibitor raltegravir was approved in 2007, offering a novel mechanism of action in suppressing HIV replication. It demonstrated high efficacy and good tolerability in clinical trials. Since then, newer generations of integrase inhibitors like elvitegravir and dolutegravir have been developed and approved. These agents have shown improved effectiveness and tolerability profiles over existing anti-HIV therapies. The introduction of integrase inhibitors has significantly expanded treatment options for HIV management. Integrase Inhibitors are primarily used in the treatment of HIV/AIDS by inhibiting the activity of the viral enzyme called integrase, thereby preventing the integration of the viral DNA into the host cell's DNA.

Market Dynamics:

The global integrase inhibitors market growth is primarily driven by the rising HIV/AIDS disease burden worldwide, increasing adoption of antiretroviral treatment (ART) for HIV, and robust product pipeline with introduction of newer and improved integrase inhibitor drugs. Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety of integrase inhibitors are major factors expected to drive growth of the global integrase inhibitors market during the forecast period. Favorable government initiatives in developed nations regarding coverage of antiretroviral therapy presents lucrative opportunities. However, the market growth can be negatively impacted by the emergence of drug-resistant strains of HIV and high costs of integrase inhibitor therapies. Key market players are engaged in R&D of long-acting injectable/oral formulations to increase adherence to treatment and drive revenue opportunities.

Key features of the study:

This report provides in-depth analysis of the global integrase inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global integrase inhibitors market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare group, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd., and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global integrase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global integrase inhibitors market.

Detailed Segmentation:

By Drug:
- Raltegravir
- Dolutegravir
- Elvitegravir
- Bictegravir
- Others (Cabotegravir, etc.)
By Route of Administration:
- Oral
- Intravenous
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Shionogi & Co., Ltd.
- Viatris Inc.

Market Dynamics
- Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety
- High Treatment Costs, Side Effects and Safety Concerns
- Integrase Inhibitors with improved therapeutic profiles.
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Integrase Inhibitors Market, By Drug, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Raltegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Dolutegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Elvitegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Bictegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others (Cabotegravir, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Integrase Inhibitors Market, By Route of Administration, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Integrase Inhibitors Market, By Distribution Channel, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Integrase Inhibitors Market, By Region, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
India
China
Japan
Australia
ASEAN
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
ViiV Healthcare group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Janssen Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Theratechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shionogi & Co., Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views

10. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

整合酶抑制劑市場：按藥物、途徑、配銷通路和地區

Integrase Inhibitors Market, By Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, and Others ), By Route of Administration, By Distribution Channel, By Geography

市場動態：

本研究的主要特點

目錄：

第1章調查目的和假設

第2章市場展望

第3章市場動態、法規及趨勢分析

第4章全球整合酶抑制劑市場 -冠狀病毒（COVID-19）大流行的影響

第5章全球整合酶抑制劑市場（按藥物），2018-2030

第6章全球整合酶抑制劑市場，依給藥途徑，2023-2030

第7章全球整合酶抑制劑市場，依配銷通路分類，2023-2030 年

第8章全球整合酶抑制劑市場，按地區，2023-2030

第9章競爭形勢

第10章章

Market Dynamics:

Key features of the study:

Detailed Segmentation:

Table of Contents:

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Integrase Inhibitors Market, By Drug, 2018-2030, (US$ Bn)

6. Global Integrase Inhibitors Market, By Route of Administration, 2023-2030, (US$ Bn)

7. Global Integrase Inhibitors Market, By Distribution Channel, 2023-2030, (US$ Bn)

8. Global Integrase Inhibitors Market, By Region, 2023-2030, (US$ Bn)

9. Competitive Landscape

10. Section

整合酶抑制劑市場：按藥物、途徑、配銷通路和地區

Integrase Inhibitors Market, By Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, and Others ), By Route of Administration, By Distribution Channel, By Geography

市場動態：

本研究的主要特點

目錄：

第1章 調查目的和假設

第2章 市場展望

第3章 市場動態、法規及趨勢分析

第4章 全球整合酶抑制劑市場 -冠狀病毒（COVID-19）大流行的影響

第5章 全球整合酶抑制劑市場（按藥物），2018-2030

第6章 全球整合酶抑制劑市場，依給藥途徑，2023-2030

第7章 全球整合酶抑制劑市場，依配銷通路分類，2023-2030 年

第8章 全球整合酶抑制劑市場，按地區，2023-2030

第9章 競爭形勢

第10章 章

Market Dynamics:

Key features of the study:

Detailed Segmentation:

Table of Contents:

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Integrase Inhibitors Market, By Drug, 2018-2030, (US$ Bn)

6. Global Integrase Inhibitors Market, By Route of Administration, 2023-2030, (US$ Bn)

7. Global Integrase Inhibitors Market, By Distribution Channel, 2023-2030, (US$ Bn)

8. Global Integrase Inhibitors Market, By Region, 2023-2030, (US$ Bn)

9. Competitive Landscape

10. Section

第1章調查目的和假設

第2章市場展望

第3章市場動態、法規及趨勢分析

第4章全球整合酶抑制劑市場 -冠狀病毒（COVID-19）大流行的影響

第5章全球整合酶抑制劑市場（按藥物），2018-2030

第6章全球整合酶抑制劑市場，依給藥途徑，2023-2030

第7章全球整合酶抑制劑市場，依配銷通路分類，2023-2030 年

第8章全球整合酶抑制劑市場，按地區，2023-2030

第9章競爭形勢

第10章章